Curis, Inc. (NASDAQ:CRIS) Sees Large Growth in Short Interest

Curis, Inc. (NASDAQ:CRIS) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 137,000 shares, an increase of 26.6% from the October 15th total of 108,200 shares. Currently, 1.8% of the company’s shares are sold short. Based on an average trading volume of 55,800 shares, the days-to-cover ratio is presently 2.5 days.

Hedge Funds Weigh In On Curis

Several large investors have recently modified their holdings of the business. Focused Wealth Management Inc increased its position in shares of Curis by 63.1% during the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after buying an additional 96,256 shares during the period. CM Management LLC increased its position in shares of Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after acquiring an additional 10,097 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Curis in a research report on Friday.

Curis Stock Performance

CRIS opened at $3.95 on Friday. The stock has a market capitalization of $23.62 million, a PE ratio of -0.51 and a beta of 3.35. Curis has a one year low of $3.51 and a one year high of $17.49. The business’s 50 day moving average price is $5.01 and its 200 day moving average price is $7.06.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.